Overview

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at high risk of recurrence.

Phase:

Phase 3

Details

Lead Sponsor:

University of Sydney

Collaborators:

Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Cancer Trials Ireland
European Organisation for Research and Treatment of Cancer - EORTC
National Health and Medical Research Council, Australia
TROG- Trans Tasman Radiation Oncology Group

Treatments:

Androgens
Nonsteroidal Anti-Androgens